Figure 3.
The risk of developing aGVHD or cGVHD depends on the timing of DLI. Landmark analysis of DLI at 30, 60, and 100 days after HCT for development of aGVHD (A-C) and cGVHD (D-F). For aGVHD, P = .007 for DLI day <30 vs ≥30; P < .001 for DLI day <60 vs ≥60, and P = .003 for DLI day <100 vs ≥100 (Gray's test). For cGVHD, P = .015 for DLI day <30 vs ≥30: P = .054 for DLI day <60 vs ≥60; P = .073 for DLI day <100 vs ≥100 (Gray's test).

The risk of developing aGVHD or cGVHD depends on the timing of DLI. Landmark analysis of DLI at 30, 60, and 100 days after HCT for development of aGVHD (A-C) and cGVHD (D-F). For aGVHD, P = .007 for DLI day <30 vs ≥30; P < .001 for DLI day <60 vs ≥60, and P = .003 for DLI day <100 vs ≥100 (Gray's test). For cGVHD, P = .015 for DLI day <30 vs ≥30: P = .054 for DLI day <60 vs ≥60; P = .073 for DLI day <100 vs ≥100 (Gray's test).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal